Fujifilm Completes Japan's Largest Bio CDMO Facility with World-Class Bioreactor Capacity
核心洞察
Fujifilm Corporation announced the completion of one of Japan's largest bio CDMO facilities at its Toyama Second Factory, marking the company's first antibody drug manufacturing plant in Japan.
The new facility features 2 x 5,000-liter mammalian cell culture bioreactors, which are among the world's largest single-use bioreactors, along with 2 x 2,000-liter bioreactors for biopharmaceutical production.
The plant will become operational in 2027 and will serve as Fujifilm's bio CDMO hub in Asia, offering end-to-end manufacturing services for antibody drugs (搜索) and antibody-drug conjugates (搜索).
FUJIFILM Corporation announced the completion of one of Japan's largest bio contract development and manufacturing organization (CDMO) facilities at the Toyama Second Factory of FUJIFILM Toyama Chemical (搜索) on December 23, 2025. The new plant represents the company's first antibody drug manufacturing facility in Japan and is scheduled to become operational in 2027.
World-Class Bioreactor Infrastructure
The facility is equipped with cutting-edge bioreactor technology, featuring 2 x 5,000-liter mammalian cell culture bioreactors that rank among the world's largest single-use bioreactors. Additionally, the plant houses 2 x 2,000-liter bioreactors to support comprehensive biopharmaceutical production capabilities.
To ensure high quality standards and accelerate technology transfer while reducing construction timelines, the facility implements Fujifilm's "kojoX™" modular facility design approach. This standardized system aligns equipment and quality management protocols with FUJIFILM Biotechnologies (搜索)' existing site in the UK.
Strategic Bio CDMO Hub for Asia
The new plant will serve as Fujifilm's bio CDMO hub in Asia, establishing end-to-end manufacturing services that span from drug substance manufacturing through finished goods and packaging. Together with an adjacent plant currently under construction, the facility will enable rapid and efficient contract manufacturing of biopharmaceuticals, including antibody drugs (搜索) and antibody-drug conjugates (搜索) (ADCs).
The site leverages FUJIFILM Toyama Chemical (搜索)'s established aseptic manufacturing expertise, developed through injectable antibiotic production, while incorporating the specialized knowledge of FUJIFILM Biotechnologies (搜索), which operates bio CDMO services across Europe and the United States.
Addressing Japan's Biopharmaceutical Manufacturing Gap
The facility addresses a critical need in Japan's biopharmaceutical landscape. Despite growing demand for biopharmaceuticals in Japan, many pharmaceutical companies currently outsource manufacturing overseas, creating challenges in process development speed and technology transfer efficiency.
Fujifilm's new manufacturing facility meets rigorous global quality standards and aims to reduce technology transfer burdens caused by language and geographical barriers. The company expects the facility to accelerate market launch timelines and contribute to stable biopharmaceutical supply chains.
Dual-Use Pandemic Preparedness
The new plant, along with an adjacent facility under construction for mRNA therapeutics and vaccines (搜索), has received selection by Japan's Ministry of Economy, Trade, and Industry (搜索) for the "Developing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production" project. This dual-use designation enables the facility to manufacture biopharmaceuticals during normal operations while maintaining the capability to switch to vaccine production during pandemic emergencies.